サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ワクチン受託製造市場- 成長、将来展望、競合分析、2023年～2031年
市場調査レポート
商品コード
1255984

ワクチン受託製造市場- 成長、将来展望、競合分析、2023年～2031年

Vaccine Contract Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日: | 発行: Acute Market Reports | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ワクチン受託製造市場- 成長、将来展望、競合分析、2023年～2031年
出版日: 2023年01月30日
発行: Acute Market Reports
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチンの豊富なラインナップと需要の高まりにより、ワクチン受託製造市場は、地域ごとに主要企業が存在し、高い競争力を持つようになりました。ワクチンの安全性や有効性とともに、自社製品を市場に投入することも重要です。ワクチン需要の高まりに対応し、均一な品質を維持するため、大手企業は市場参入を早めるために、ワクチンの製造を第三者に委託する傾向にあります。

地域ごとの予防接種に対する意識の高まりは、ワクチン受託製造の市場全体の成長に寄与しています。また、世界的に予防接種を義務付ける政府の取り組みが、ワクチン需要の高まりにつながっています。世界保健機関（WHO）による世界ワクチン行動計画（GVAP）は、2020年までにワクチンへのアクセス拡大を通じて死亡を予防するためのイニシアチブです。2017年5月現在、194カ国の保健省が、GVAPの目標を達成するための予防接種強化に関する新たな取り組みに賛同しています。WHOの発表によると、世界で約1,950万人の乳幼児に必要なワクチンがまだ提供されていないとのことです。ワクチンに対するニーズはますます高まっており、既存企業は主に他の分子の開発に注力しているため、アウトソーシングを選択することがほとんどです。また、新興国では、適切な製造設備や熟練した労働力がないため、市場標準に対応するために、製造委託先と契約する必要があります。

ワクチンの受託製造業者は、適正製造基準（GMP）を遵守し、品質保証のための審査書類を提供します。ワクチン製造の新たな進歩に伴い、製造委託業者は常に製造設備をアップグレードし、最新のサービスを提供しています。産業界のリーダーによる初期開発プロセスでは、プロセスの拡張のためにサードパーティがアプローチしています。

継続的なパートナーシップと買収は、市場全体の成長をさらに加速させます。2017年10月、がん治療用の樹状細胞ワクチンを開発しているDCPrime BVは、apceth Biopharma GmbHの受託製造業者と協業しました。この提携は、臨床バッチ生産とがんワクチンの拡張スケール製造プロセスの開発からなります。しかし、一部の大手製薬会社は、経営上の不測の事態や安全性・有効性の逸脱のリスクを回避するため、ワクチンの製造を自社で行うことを希望しています。この要因は、予測期間中、契約ベースのサービスの世界の導入にマイナスの影響を与える可能性があります。

目次

第1章 序文

  • レポート内容
    • 報告書の目的
    • 対象読者
    • 主な提供商品
  • 市場セグメンテーション
  • 調査手法
    • フェーズI-二次調査
    • フェーズII-一次調査
    • フェーズIII-有識者別レビュー
    • 前提条件
    • 採用したアプローチ

第2章 エグゼクティブサマリー

  • 市場のスナップショット：世界のワクチン受託製造市場
  • 世界のワクチン受託製造市場：サービス別 2022
  • 世界のワクチン受託製造市場：用途別 2022
  • 世界のワクチン受託製造市場：地域別 2022
  • 魅力的な投資提案：地域別 2022

第3章 ワクチン受託製造市場：競合分析

  • 主要ベンダーの市場ポジショニング
  • ベンダーが採用する戦略
  • 主要な産業戦略
  • ティア分析：2022 vs. 2031

第4章 ワクチン受託製造市場：マクロ分析と市場力学

  • イントロダクション
  • 世界のワクチン受託製造市場金額 2021-2031
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析

第5章 ワクチン受託製造市場：サービス別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs. 2031
  • 市場セグメンテーション
    • 細胞株/株の開発
    • 上流工程開発
    • 下流工程開発
    • 分析開発
    • 安定性試験
    • 製品リリース

第6章 ワクチン受託製造市場：用途別 2021-2031

  • 市場概要
  • 成長・収益分析：2022 vs. 2031
  • 市場セグメンテーション
    • 人間の使用
    • 獣医

第7章 北米のワクチン受託製造市場 2021-2031

  • 市場概要
  • ワクチン受託製造市場：サービス別 2021-2031
  • ワクチン受託製造市場：用途別 2021-2031
  • ワクチン受託製造市場：地域別 2021-2031
    • 北米
      • 米国
      • カナダ
      • その他北米地域

第8章 英国と欧州連合のワクチン受託製造市場 2021-2031

  • 市場概要
  • ワクチン受託製造市場：サービス別 2021-2031
  • ワクチン受託製造市場：用途別 2021-2031
  • ワクチン受託製造市場：地域別 2021-2031
    • 英国と欧州連合
      • 英国
      • ドイツ
      • スペイン
      • イタリア
      • フランス
      • その他欧州地域

第9章 アジア太平洋ワクチンの受託製造市場 2021-2031

  • 市場概要
  • ワクチン受託製造市場：サービス別 2021-2031
  • ワクチン受託製造市場：用途別 2021-2031
  • ワクチン受託製造市場：地域別 2021-2031
    • アジア太平洋
      • 中国
      • 日本
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域

第10章 ラテンアメリカのワクチン受託製造市場 2021-2031

  • 市場概要
  • ワクチン受託製造市場：サービス別 2021-2031
  • ワクチン受託製造市場：用途別 2021-2031
  • ワクチン受託製造市場：地域別 2021-2031
    • ラテンアメリカ
      • ブラジル
      • メキシコ
      • その他ラテンアメリカ地域

第11章 中東・アフリカのワクチン受託製造市場 2021-2031

  • 市場概要
  • ワクチン受託製造市場：サービス別 2021-2031
  • ワクチン受託製造市場：用途別 2021-2031
  • ワクチン受託製造市場：地域別 2021-2031
    • 中東・アフリカ
      • GCC
      • アフリカ
      • その他中東・アフリカ地域

第12章 企業プロファイル

  • Ajinomoto Althea Inc.
  • Albany Molecular Research Inc.
  • Cobra Biologics & Pharmaceutical Services
  • Cytovance Biologics
  • Catalent Inc.
  • FUJIFILM Diosynth Biotechnologies U.S.A. Inc.
  • ICON plc.
  • IDT Biologika GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Paragon Bioservices Inc.
  • PRA Health Sciences
  • Others notable players
図表

List of Tables

  • TABLE 1 Global Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 2 Global Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 3 North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 4 North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 5 U.S. Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 6 U.S. Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 7 Canada Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 8 Canada Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 9 Rest of North America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 10 Rest of North America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 11 UK and European Union Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 12 UK and European Union Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 13 UK Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 14 UK Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 15 Germany Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 16 Germany Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 17 Spain Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 18 Spain Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 19 Italy Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 20 Italy Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 21 France Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 22 France Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 23 Rest of Europe Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 24 Rest of Europe Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 25 Asia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 26 Asia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 27 China Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 28 China Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 29 Japan Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 30 Japan Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 31 India Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 32 India Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 33 Australia Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 34 Australia Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 35 South Korea Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 36 South Korea Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 37 Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 38 Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 39 Brazil Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 40 Brazil Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 41 Mexico Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 42 Mexico Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 43 Rest of Latin America Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 44 Rest of Latin America Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 45 Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 46 Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 47 GCC Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 48 GCC Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 49 Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 50 Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Service, 2021-2031, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Vaccine Contract Manufacturing Market By Application, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global Vaccine Contract Manufacturing Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Vaccine Contract Manufacturing Market: Quality Assurance
  • FIG. 5 Global Vaccine Contract Manufacturing Market, By Service, 2022
  • FIG. 6 Global Vaccine Contract Manufacturing Market, By Application, 2022
  • FIG. 7 Global Vaccine Contract Manufacturing Market, By Geography, 2022
  • FIG. 8 Market Geographical Opportunity Matrix - Global Vaccine Contract Manufacturing Market, 2022
  • FIG. 9 Market Positioning of Key Vaccine Contract Manufacturing Market Players, 2022
  • FIG. 10 Global Vaccine Contract Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
  • FIG. 11 Global Vaccine Contract Manufacturing Market, By Service, 2022 Vs 2031, %
  • FIG. 12 Global Vaccine Contract Manufacturing Market, By Application, 2022 Vs 2031, %
  • FIG. 13 U.S. Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 14 Canada Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 15 Rest of North America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 16 UK Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 17 Germany Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 18 Spain Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 19 Italy Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 20 France Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 21 Rest of Europe Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 22 China Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 23 Japan Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 24 India Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 25 Australia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 26 South Korea Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 27 Rest of Asia Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 28 Brazil Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 29 Mexico Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 30 Rest of Latin America Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 31 GCC Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 32 Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
  • FIG. 33 Rest of Middle East and Africa Vaccine Contract Manufacturing Market (US$ Million), 2021 - 2031
目次
Product Code: 137988-01-23

An extensive portfolio of vaccines and constant rising demand has rendered the vaccine contract manufacturing market to be highly competitive with vast presence of key players across geographies. Along with safety and effectiveness of vaccines, flooding the market with one's product clutches equal importance. In order to cater to the rising demand for vaccines and maintaining uniform quality, leading industrial players tend to outsource manufacturing of vaccines to third parties to expedite market entry.

Rising awareness of immunization across geographies contributes to the overall market growth of vaccine contract manufacturing. Additionally, government initiatives enforcing immunization globally has led to rising vaccine demand. The Global Vaccine Action Plan (GVAP) by the World Health Organization (WHO) is an initiative to prevent deaths via expanding the access of vaccines by 2020. As of May 2017, Health ministries across 194 countries endorsed a new initiative on strengthening immunization to meet the goals of GVAP. As per the WHO, around 19.5 million infants worldwide were still not provided with necessary vaccines. The ever-rising need for vaccines, and with established players primarily focusing on the development of other molecules, outsourcing is mostly the preferred choice. Additionally, in developing nations, the lack of suitable manufacturing set up and skilled labour compels them to engage with contract manufacturers in order to cater to market standards.

Vaccine contract manufacturers comply with the Good Manufacturing Practices and provide concerned quality assurance review documents. With newer advancements in vaccine production, the contract vendors constantly upgrade their production facilities providing up-to-date services. With initial development process taking place by industrial leaders, third parties are approached for scaling up processes.

Continuous partnerships and acquisitions further catalyse the overall market growth. In October 2017, DCPrime BV a firm developing dendritic cell vaccines for cancer therapy collaborated with apceth Biopharma GmbH contract manufacturer. The collaboration comprises clinical batch production and the development of an expanded scale manufacturing process for cancer vaccines. However, a few large pharmaceutical firms prefer to maintain vaccine manufacturing in-house to avoid risks of management contingencies and deviation in safety and efficacy. This factor could have a negative impact on the global adoption of contract-based services during the forecast period.

Rising demand for expedited entry of vaccines into the market has rendered the vaccine contract manufacturing market to be highly competitive with a vast outreach across geographies. The key industrial players enjoying a dominant position in this market are Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Cobra Biologics & Pharmaceutical Services, Cytovance Biologics; Catalent, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON plc., IDT Biologika GmbH, Lonza Group, Ltd., Merck KGaA, Paragon Bioservices, Inc., PRA Health Sciences and Others notable players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Vaccine Contract Manufacturing market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Vaccine Contract Manufacturing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Service

Cell line/strain development

Upstream process development

Downstream process development

Analytical development

Stability testing

Product release

Application

Human use

Veterinary

Region Segment (2021-2031; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Vaccine Contract Manufacturing market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2031.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Vaccine Contract Manufacturing market?

Which is the largest regional market for Vaccine Contract Manufacturing market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Vaccine Contract Manufacturing market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Vaccine Contract Manufacturing market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Vaccine Contract Manufacturing Market
  • 2.2. Global Vaccine Contract Manufacturing Market, By Service, 2022 (US$ Million)
  • 2.3. Global Vaccine Contract Manufacturing Market, By Application, 2022 (US$ Million)
  • 2.4. Global Vaccine Contract Manufacturing Market, By Geography, 2022 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2022

3. Vaccine Contract Manufacturing Market: Competitive Analysis

  • 3.1. Market Positioning of Key Vaccine Contract Manufacturing Market Vendors
  • 3.2. Strategies Adopted by Vaccine Contract Manufacturing Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. Vaccine Contract Manufacturing Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Vaccine Contract Manufacturing Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. Cell line/strain development
    • 5.3.2. Upstream process development
    • 5.3.3. Downstream process development
    • 5.3.4. Analytical development
    • 5.3.5. Stability testing
    • 5.3.6. Product release

6. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Human use
    • 6.3.2. Veterinary

7. North America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 7.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 7.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 7.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

8. UK and European Union Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 8.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 8.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 8.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

9. Asia Pacific Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 9.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 9.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.4.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.5.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 9.4.1.6.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

10. Latin America Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 10.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 10.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 10.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

11. Middle East and Africa Vaccine Contract Manufacturing Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
  • 11.3. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
  • 11.4.Vaccine Contract Manufacturing Market: By Region, 2021-2031, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.1.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.2.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Vaccine Contract Manufacturing Market: By Service, 2021-2031, USD (Million)
        • 11.4.1.3.1. Vaccine Contract Manufacturing Market: By Application, 2021-2031, USD (Million)

12. Company Profile

  • 12.1. Ajinomoto Althea, Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Albany Molecular Research, Inc.
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Cobra Biologics & Pharmaceutical Services
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Cytovance Biologics
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Catalent, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. ICON plc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. IDT Biologika GmbH
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Lonza Group, Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives
  • 12.10. Merck KGaA
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Portfolio
    • 12.10.4. Strategic Initiatives
  • 12.11. Paragon Bioservices, Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Portfolio
    • 12.11.4. Strategic Initiatives
  • 12.12. PRA Health Sciences
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Portfolio
    • 12.12.4. Strategic Initiatives
  • 12.13. Others notable players
    • 12.13.1. Company Overview
    • 12.13.2. Financial Performance
    • 12.13.3. Product Portfolio
    • 12.13.4. Strategic Initiatives